Drucken18.10.2021

Startseite Institute Molekulare und Klinische Im... Forschung Arbeitsgruppen AG Fischer Publikationen

Publikationen

Publikationen der letzten 5 Jahre (Experimentelle Hämatologie)

Müller P, Baldauf CK, Haage TR, Waldleben AM, Richter F, Pfizenmaier K, Fischer T.
Anti-inflammatory treatment in MPN: Targeting TNFα-receptor 1 (TNFR1) and TNFR2 in JAK2-V617F induced disease.
Blood Adv. 2021 Sep 30:bloodadvances.2021004438. doi: 10.1182/bloodadvances.2021004438. Online ahead of print. Imp.-Fact.: 6,686

Baldauf CK, Müller P, Haage TR, Adam-Frey S, Lokau J, Garbers C, Fischer T.
Anti-IL-6 cytokine treatment has no impact on elevated hematocrit and splenomegaly in a polycythemia vera mouse model.
Blood Adv. 2021 Sep 24:bloodadvances.2021004379. doi: 10.1182/bloodadvances.2021004379. Online ahead of print. Imp.-Fact.: 6,686

Dudeck J, Kotrba J, Immler R, Hoffmann A, Voss M, Alexaki VI , Morton L, Jahn SR, Katsoulis-Dimitriou K, Winzer S, Kollias Georg, Fischer T, Nedospasov SA, Dunay IR, Chavakis T, Müller A J, Schraven B, Sperandio M, Dudeck A.
Directional mast cell degranulation of tumor necrosis factor into blood vessels primes neutrophil extravasation.
Immunity, 2021; Mar 9;54(3):468-483.e5. doi: 10.1016/j.immuni.2020.12.017. Epub 2021 Jan 22. Imp.-Fact.:22,553

Osbelt L, Wende M, Almási E, Derksen E, Muthukumarasamy U, Lesker TR, Galvez EJC, Pils MC, Schalk E, Chhatwal P, Färber J, Neumann-Schaal M, Fischer T, Schlüter D, Strowig T.
Klebsiella oxytoca causes colonization resistance against multidrug-resistant K. pneumoniae in the gut via cooperative carbohydrate competition.
Cell Host Microbe 2021; 2021 Sep 29;S1931-3128(21)00419-4. doi: 10.1016/j.chom.2021.09.003. Online ahead of print. Imp.-Fact.:21,023

Rummelt C, Gorantla SP, Meggendorfer M, Charlet A, Endres C, Döhner K, Heidel FH, Fischer T, Haferlach T, Duyster J, von Bubnoff N.
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
Leukemia. 2020 Nov 4. Imp.-Fact.:8,665

Jost F, Schalk E, Weber D, Doehner H, Fischer T, Sager S.
Model-based optimal AML consolidation treatment.
IEEE Trans Biomed Eng 2020;67(12):3296-3306. Imp.-Fact.:4,424

Lilienthal P, Tetschke M, Schalk E, Fischer T, Sager S.
Optimized and personalized phlebotomy schedules for patients suffering from polycythemia vera.
Front Physiol 2020;11:328. Imp.-Fact.:3,2

Nimmagadda SC, Frey S, Müller P, Wolleschak D, Weinert S, Keller U, Edelmann B, Fischer T.
SDF1a-induced chemotaxis of JAK2-V617F positive cells is dependent on Bruton's Tyrosine Kinase and its downstream targets PI3K/AKT, PLC gamma 1 and RhoA.
Haematologica. 2019 Jul;104(7):e288-e292. Imp.-Fact.:9,09

Hillert LK, Bettermann-Bethge K, Nimmagadda SC, Fischer T, Naumann M, Lavrik IN.
Targeting RIPK1 in AML cells carrying FLT3-ITD.
Int J Cancer. 2019 Mar 3. [Epub ahead of print] Imp.-Fact.:7,36

Lowinus T, Heidel FH, Bose T, Nimmagadda SC, Schnöder T, Cammann C, Schmitz I, Seifert U, Fischer T, Schraven B, Bommhardt U.
Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling.
Cell Commun Signal. 2019 Jan 16;17(1):5. Imp.-Fact.:5,324

Jost F, Schalk E, Rinke K, Fischer T, Sager S.
Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia.
PLoS One 2019;14(7):e0204540. Imp.-Fact.:2,806

Edelmann B, Gupta N, Schnöder T, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC , Nimmagadda SC, Müller P, Braun-Dullaeus RC, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel F, Schraven B, Isermann B, Müller AJ, Fischer T.
JAK2-V617F promotes venous thrombosis through ß1/ß2 integrin activation.
J Clin Invest. 2018;128(10):4359-4371. Imp.-Fact.:13,25

Maifrede S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik M, Huang J, Skorski T.
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Blood. 2018 May 21. pii: blood-2018-02-834895.[Epub ahead of print] Imp.-Fact.:13,164

Marhäll A, Heidel F, Fischer T, Rönnstrand L.
Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Ann Hematol. 2018 May;97(5):773-780. Imp.-Fact.:3,083

Lilienthal P, Tetschke M, Pottgiesser T, Fischer T, Schalk E, Sager S.
Mathematical Modeling of RBC count dynamics after blood loss.
Processes 2018;6(9):157. Imp.-Fact.:1,279

Ranjan S, Goihl A, Kohli S, Gadi I, Pierau M, Shahzad K, Gupta D, Bock F, Wang H, Shaikh H, Kähne T, Reinhold D, Bank U, Zenclussen AC, Niemz J, Schnöder TM, Brunner-Weinzierl M, Fischer T, Kalinski T, Schraven B, Luft T, Huehn J, Naumann M, Heidel FH, Isermann B.
Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.
Nat Commun. 2017 Aug 21;8(1):311. Imp.-Fact.:12,124

Gupta N, Edelmann B, Schnoeder TM, Saalfeld FC, Wolleschak D, Kliche S, Schraven B, Heidel FH, Fischer T.
JAK2-V617F activates ß1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1.
Leukemia. 2017 May;31(5):1223-1226. Epub 2017 Jan 18. Imp.-Fact.:10,023

Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D.
Gain of function in Jak2V617F-positive T-cells.
Leukemia. 2017 Apr;31(4):1000-1003. Imp.-Fact.:10,023

Gieseler-Halbach S, Meltendorf S, Pierau M, Weinert S, Heidel FH, Fischer T, Handschuh J, Braun-Dullaeus RC, Schrappe M, Lindquist JA, Mertens PR, Thomas U, Brunner-Weinzierl MC.
RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts.
Cell Death Differ. 2017 Feb;24(2):371-383. Epub 2016 Dec 23. Imp.-Fact.:8,339

Arra A, Lingel H, Kuropka B, Pick J, Schnoeder T, Fischer T, Freund C, Pierau M, Brunner-Weinzierl MC.
The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs.
Oncoimmunology. 2017 Jan 20;6(2):e1273300. Imp.-Fact.:7,719

Bongartz H, Hessenkemper W, Müller C, Fensky M, Fritsch J, Mandel K, Behrmann I, Haan C, Fischer T, Feller SM, Schaper F.
The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
Cell Signal. 2017 Jul;35:37-47. Imp.-Fact.:3,937

Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH.
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
J Cancer Res Clin Oncol. 2017 May;143(5):807-820. Imp.-Fact.:3,503

Lipka DB, Wagner MC, Dziadosz M, Fischer T.
Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT-ITD-positive leukemias.
Leukemia. 2016 May 24. Imp.-Fact.:12,104

Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schröder K, Shah AM, Fischer M, Scholl S, Barth J, Oellerich T, Berg T, Serve H, Frey S, Fischer T, Heidel FH, Böhmer FD.
NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD positive AML cells.
Leukemia. 2016 Feb;30(2):473-83. Epub 2015 Aug 26. Imp.-Fact.:11,702

Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, Heidel FH.
Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.
Leukemia. 2016 Apr;30(4):991-5. Imp.-Fact.:11,702

Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong S, Döhner K, Fischer T, Heidel FH.
Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.
Leukemia. 2016 May;30(5):1220-5. Imp.-Fact.:11,702

Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z.
Leukemogenic potency of the novel FLT3-N676K mutant.
Ann Hematol. 2016 Apr;95(5):783-91. Imp.-Fact.:2,634

Perner F, Schnöder TM, Fischer T, Heidel FH.
Kinomics Screening Identifies Aberrant Phosphorylation of CDC25C in FLT3-ITD-positive AML.
Anticancer Res. 2016 Dec;36(12):6249-6258. Imp.-Fact.:1,826

Jost F, Rinke K, Fischer T, Schalk E, Sager S.
Optimum experimental design for patient specific mathematical leukopenia models.
IFAC-PapersOnLine 2016;49(26):344-349.

Rinke K, Jost F, Findeisen R, Fischer T, Bartsch R. Schalk E, Sager, S
Parameter estimation for leukocyte dynamics after chemotherapy
IFAC-PapersOnLine - Frankfurt: Elsevier, Bd. 49.2016, 26, S. 44-49

Drucken